Alzheimer's Disease: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797410
  • Drug Pipelines
  • 366 pages
  • Datamonitor Healthcare
1 of 3
Amyloid-targeting immunotherapies may create a $10bn opportunity within the Alzheimer’s disease market.

This report addresses the following questions:

- How will the approval of immunotherapies affect Alzheimer’s disease treatment dynamics?
- Which patient subgroups and drug class will have the largest impact on Alzheimer’s disease market sales?
- How will the market perceive the approval of additional symptomatic pipeline drugs?
- What are the unmet needs in Alzheimer’s disease that could be addressed by drug companies?
- What are the most commonly prescribed therapies for Alzheimer’s disease across each disease severity?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: ALZHEIMER’S DISEASE

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- aducanumab
- Aricept (donepezil)
- crenezumab
- encenicline
- Exelon/Exelon Patch (rivastigmine)
- idalopirdine
- Namenda/XR (memantine)
- Razadyne (galantamine)
- RVT-1
- solanezumab
- Primary Research Methodology

TREATMENT: ALZHEIMER'S DISEASE

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Alzheimer’s Disease

EPIDEMIOLOGY: ALZHEIMER'S DISEASE IN BRAZIL

- Executive Summary
- Disease Definition and Diagnosis
- Global Variations
- Risk Factors
- Sources and Methodology
- Forecast
- Discussion
- Bibliography

EPIDEMIOLOGY: ALZHEIMER’S DISEASE IN THE US, JAPAN, AND 5EU

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix

MARKETED DRUGS: ALZHEIMER'S DISEASE

- Executive Summary
- Product Overview
- Product profile: Aricept
- Product profile: Exelon/Exelon Patch
- Product profile: Namenda
- Product profile: Razadyne

PIPELINE: ALZHEIMER’S DISEASE

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): LMTX
- Product profile (late stage): RVT-1
- Product profile (late stage): aducanumab
- Product profile (late stage): azeliragon
- Product profile (late stage): crenezumab
- Product profile (late stage): encenicline
- Product profile (late stage): gantenerumab
- Product profile (late stage): idalopirdine
- Product profile (late stage): solanezumab
- Product profile (late stage): verubecestat
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll